Organization | Canadian Immunization Research Network

Canadian Immunization Research Network Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Halifax Canada (2014)

Organization Overview

First Clinical Trial

2014

NCT02169674

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Canadian Immunization Research Network

Active Ingredients

Drugs in Phase 4 Trials (7)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

diphtheria toxoid (1 trial)

DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (3 trials)

tetanus toxoid (1 trial)

Drugs in Phase 2 Trials (4)

bnt162b2 (Comirnaty) (1 trial)

bpsc-1001 vaccine (1 trial)

chadox1 (1 trial)

mrna-1273 (Spikevax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hemorrhagic Fever, Ebola (Phase 2)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Meningococcal Infections (Phase 4)

Pneumococcal Infections (Phase 3)

Pneumonia (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 11